Safety, PK, and Food Effect of BI 1584862 in Healthy Males

Phase 1, randomised, single-blind trial of BI 1584862 in geographic atrophy (GA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator up to 14 days, Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 to the last quantifiable data point up to 6 days and 1 more. Started Sep 2022; status: completed.